Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals.

MLA

Liu, Yen-Chun, et al. “Higher End-of-Treatment HBsAg Levels Is Associated with Later Onset but Not Severe Relapse in HBeAg-Negative Chronic Hepatitis B Patients Stopping Antivirals.” Alimentary Pharmacology & Therapeutics, vol. 59, no. 6, Mar. 2024, pp. 762–73. EBSCOhost, https://doi.org/10.1111/apt.17880.

APA

Liu, Y.-C., Jeng, W.-J., Peng, C.-W., Chien, R.-N., & Liaw, Y.-F. (2024). Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary Pharmacology & Therapeutics, 59(6), 762–773. https://doi.org/10.1111/apt.17880

Chicago

Liu, Yen-Chun, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, and Yun-Fan Liaw. 2024. “Higher End-of-Treatment HBsAg Levels Is Associated with Later Onset but Not Severe Relapse in HBeAg-Negative Chronic Hepatitis B Patients Stopping Antivirals.” Alimentary Pharmacology & Therapeutics 59 (6): 762–73. doi:10.1111/apt.17880.